<?xml version="1.0" encoding="UTF-8"?>
<p id="Par4">Highly symptomatic cases were recognized in Sydney, Australia, and also detected nationally in 2013/14
 <sup>
  <xref ref-type="bibr" rid="CR16">16</xref>â€“
  <xref ref-type="bibr" rid="CR18">18</xref>
 </sup>. It was again seen in epidemics in 2015/16
 <sup>
  <xref ref-type="bibr" rid="CR19">19</xref>
 </sup> and more recently in 2017/18
 <sup>
  <xref ref-type="bibr" rid="CR4">4</xref>
 </sup>. The earliest published HPeV3 positive sample in Australia was collected from a sick infant in 2012
 <sup>
  <xref ref-type="bibr" rid="CR20">20</xref>
 </sup>. This 2012 virus was most similar to an HPeV3 identified in an outbreak in children and adults with myalgia in Yamagata, Japan in 2011
 <sup>
  <xref ref-type="bibr" rid="CR21">21</xref>
 </sup>. Between 2012 and 2013, a recombination event between a Yamagata-2011 like virus and an unidentified parechovirus occurred forming an Australian recombinant HPeV3. This virus became the predominant HPeV3 identified in the 2013/14 and 2015/16 epidemics in Australia
 <sup>
  <xref ref-type="bibr" rid="CR19">19</xref>,
  <xref ref-type="bibr" rid="CR20">20</xref>
 </sup>.
</p>
